Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations
The impact of IMDC risk model on survival was modest in IO-IO, while remained statistically substantial in IO-TKI. Survival outcomes did not significantly differ between IO-IO and IO-TKI during the short follow-up period.
Authors
- Masato Kikuta
- Yuki Takai (ORCID: https://orcid.org/0000-0001-6506-5313)
- Nobuo Shinohara (ORCID: https://orcid.org/0000-0002-6695-294X)
- Tomonori Habuchi (ORCID: https://orcid.org/0000-0003-0998-4432)
- Takafumi Narisawa (ORCID: https://orcid.org/0000-0003-4062-2675)
- Kazuyuki Numakura (ORCID: https://orcid.org/0000-0002-5899-1738)
- Sei Naito (ORCID: https://orcid.org/0000-0002-6104-4344)
- Norihiko Tsuchiya (ORCID: https://orcid.org/0000-0003-4242-2618)
- Mayu Yagi
- Yuya Sekine
- Ojiro Tokairin
- Takahiro Osawa
Institutions
- Yamagata University (JP)
- Akita University (JP)
- Hokkaido University (JP)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1186/s12885-025-13504-6
- Citations
- 2
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04